More on GYRE
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $7.83 |
|
|||
| Open | $8.23 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $8.47 | ||||
| Day Low | $7.57 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 219,420 | ||||
- H.C. Wainwright Reiterates Buy Rating on Gyre Therapeutics (GYRE) following acquisition announcement
- Form 8-K GYRE THERAPEUTICS, INC. For: Mar 02
- Gyre Therapeutics to acquire Cullgen for $300 million in stock
- Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline
- Form 4 GYRE THERAPEUTICS, INC. For: Jan 07 Filed by: Chen Ruoyu
- Form 4 GYRE THERAPEUTICS, INC. For: Jan 07 Filed by: Zhang Ping
- Gyre Therapeutics receives CDE alignment on conditional approval pathway for Hydronidone
- Form 8-K GYRE THERAPEUTICS, INC. For: Jan 05
- Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
- Form 144 GYRE THERAPEUTICS, INC. Filed by: Ye Weiguo
Entities mentioned with GYRE
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- H.C. Wainwright | View Related Stories »
- FDA | View Related Stories »
- Jefferies & Co | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
